Satty, Alexandra M. http://orcid.org/0000-0002-7840-860X
Klein, Elizabeth http://orcid.org/0000-0002-9735-4862
Mauguen, Audrey
Kunvarjee, Binni http://orcid.org/0000-0002-8255-7982
Boelens, Jaap Jan http://orcid.org/0000-0003-2232-6952
Cancio, Maria
Curran, Kevin J.
Kernan, Nancy A.
Prockop, Susan E. http://orcid.org/0000-0003-4175-5728
Scaradavou, Andromachi http://orcid.org/0000-0003-2425-1069
Spitzer, Barbara
Tamari, Roni http://orcid.org/0000-0002-2386-0850
Ruggiero, Julianne
Torok-Castanza, Joanne
Mehta, Parinda A.
O’Reilly, Richard J.
Boulad, Farid
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
Article History
Received: 22 May 2023
Revised: 11 September 2023
Accepted: 19 September 2023
First Online: 29 September 2023
Competing interests
: JJB – consulting Sobi, Omeros, Bluebird Bio, Bluerock, Sanofi, Advanced Clinical, Immusoft; KJC – Serves on the advisory board/consulting for Novartis, Atara Biotherapeutics, and Turn Bio. He receives research funding from Novartis, Celegene, Cellectis. SEP – Receives support for the conduct of clinical trials from Atara Biotherapeutics, AlloVir, and Jasper. Consulting for CellEvolve, Pierre Fabre and Regeneron. IP related to development of adoptive T cell therapies with all rights assigned to MSKCC; ROR received royalties following licensure of the EBV-specific T-cell bank by Atara Biotherapeutics and has subsequently received research support and consultant fees from Atara Biotherapeutics. The other authors declare no competing interests.